Pharmacokinetic Consequences of Pegylation

Figures & data

TABLE 1 Pegylated drugs approved by the FDA

Trade name	Generic name	Approval date	Company
Adagen	Pegademase	03/21/1990	Enzon
Oncaspar	Pegaspargase	02/01/1994	Enzon
Peg-Intron	Peginterferon alfa-2b	01/19/2001	Schering
Neulasta	Pegfilgrastim	01/31/2002	Amgen
Pegasys	Peginterferon alfa-2a	10/16/2002	Hoffman-la roche
Somavert	Pegvisomant	03/25/2003	Pharmacia and Upjohn
Peginterferon	Peginterferon alfa-2a	06/04/2004	Hoffman-la roche
Acumen	Pegaptanib sodium	12/17/2004	Eyetech

http://www.accessdata.fda.gov/scripts/cder/drugsatfda

FIG. 1 Typical molecular structures of poly-ethylene glycols (PEGs).

FIG. 2 First-generation irreversible PEG reactive forms (Roberts et al. 2002).

FIG. 3 Second-generation irreversible PEG reactive forms (Roberts et al. 2002).

Roberts M. J., Bentley M. D., Harris J. M. Chemistry for peptide and protein PEGylation. Adv. Drug Del. Rev. 2002; 54: 459–476, [CSA], [CROSSREF]

 PubMed Web of Science ®Google Scholar